Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Fars K. Alanazi, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 3287-3311
Open Access | Times Cited: 22

Showing 22 citing articles:

Advances and challenges in the treatment of lung cancer
Yuting Li, Bingshuo Yan, Shiming He
Biomedicine & Pharmacotherapy (2023) Vol. 169, pp. 115891-115891
Open Access | Times Cited: 144
Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Ahmad Abdul-Wahhab Shahba, et al.
Molecules (2023) Vol. 28, Iss. 1, pp. 448-448
Open Access | Times Cited: 20
BV2 Membrane‐Coated PEGylated‐Liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy
Heng‐Cai Wang, Wei Yang, Ling Xu, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 19
Closed Access | Times Cited: 6
Cannabidiol-Loaded Solid Lipid Nanoparticles Ameliorate the Inhibition of Proinflammatory Cytokines and Free Radicals in an In Vitro Inflammation-Induced Cell Model
Khent Primo Alcantara, John Wilfred T. Malabanan, Nonthaneth Nalinratana, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4744-4744
Open Access | Times Cited: 5
Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions
Ramin Yousefpour Shahrivar, Zahra Ahmadi Fakhr, Elham Abbasgholinejad, et al.
Advanced Therapeutics (2023) Vol. 6, Iss. 12
Closed Access | Times Cited: 12
Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons
Gamaleldin I. Harisa, Abdelrahman Y. Sherif, Fars K. Alanazi
The Journal of Membrane Biology (2023) Vol. 256, Iss. 3, pp. 199-222
Open Access | Times Cited: 10
Ciprofloxacin-encapsulated solid lipid nanoparticles: a comprehensive biochemical analysis of cytotoxic effects, proliferation inhibition, and apoptotic induction in KG1-a leukemia cells
S. Kadhim, Gholamreza Dehghan, Majid Mahdavi
Medical Oncology (2025) Vol. 42, Iss. 3
Closed Access
Formulation of PEGylated solid lipid nanoparticles for improving bioavailability of pravastatin: Optimization, ex vivo, and in vivo studies
Seema Yadav, Narahari N. Palei, Ramesh Kumar Gupta, et al.
Journal of Dispersion Science and Technology (2025), pp. 1-15
Closed Access
PERMEABILITY ENHANCEMENT OF A BCS CLASS III DRUG THROUGH LIPID-BASED NANOPARTICLES: A QUALITY BY DESIGN APPROACH
M. Bhavani, Saravanan Ravindran
International Journal of Applied Pharmaceutics (2025), pp. 170-179
Open Access
Gene-editing technology, from macromolecule therapeutics to organ transplantation: Applications, limitations, and prospective uses
Gamaleldin I. Harisa, Tarek M. Faris, Abdelrahman Y. Sherif, et al.
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127055-127055
Closed Access | Times Cited: 9
TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies
Gamaleldin I. Harisa, Abdelrahman Y. Sherif, Fars K. Alanazi, et al.
Colloids and Surfaces B Biointerfaces (2023) Vol. 223, pp. 113148-113148
Closed Access | Times Cited: 8
Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles
Ehab M. Elzayat, Abdelrahman Y. Sherif, Fahd A. Nasr, et al.
Materials (2023) Vol. 16, Iss. 15, pp. 5364-5364
Open Access | Times Cited: 8
Emerging Nanotechnology-based Therapeutics: A New Insight into Promising Drug Delivery System for Lung Cancer Therapy
Ravinder Verma, Lakshita Rao, Diksha Nagpal, et al.
Recent Patents on Nanotechnology (2023) Vol. 18, Iss. 4, pp. 395-414
Closed Access | Times Cited: 6
The Chimera of TPGS and Nanoscale Lipid Carriers as Lymphatic Drug Delivery Vehicles to Fight Metastatic Cancers
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Fars K. Alanazi
Current Drug Delivery (2023) Vol. 21, Iss. 4, pp. 525-543
Closed Access | Times Cited: 5
Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells
Ibrahim A. Aljuffali, Md. Khalid Anwer, Mohammed Muqtader Ahmed, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1549-1549
Open Access | Times Cited: 4
Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Ahmad Abdul-Wahhab Shahba, et al.
Drug Development Research (2023) Vol. 84, Iss. 7, pp. 1453-1467
Closed Access | Times Cited: 3
Amelioration of The Therapeutic Potential of Gefitinib Against Breast Cancer Using Nanostructured Lipid Carriers
Pankaj Kumar, Bharti Mangla, Shamama Javed, et al.
Nanomedicine (2023) Vol. 18, Iss. 18, pp. 1139-1160
Closed Access | Times Cited: 2
SLN Mediate Active Delivery of Gefitinib into A549 Cell Line: Optimization, Biosafety and Cytotoxicity Studies
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Fars K. Alanazi
Drug Delivery Letters (2022) Vol. 13, Iss. 2, pp. 133-150
Closed Access | Times Cited: 4
Tyloxapol and nanoliposomes induce selective delivery of 5‐fluorouracil into hepatic tissues via VLDL/LDL‐mediated pathway
Gamaleldin I. Harisa, Saleh A. Alanazi, Mohamed M. Badran, et al.
European Journal of Lipid Science and Technology (2023)
Closed Access | Times Cited: 2
Lipid-Based Carriers for Targeting Lymphatic System
Komal Parmar, Jayvadan K. Patel
(2024), pp. 229-241
Closed Access
Solid Dispersions of Gefitinib with D-α-Tocopherol Polyethylene Glycol-1000 Succinate and 2-Hydroxypropyl β-Cyclodextrin Complex Improved Their Solubility, Dissolution and Apoptosis against A549 Cells
Mohd Abul Kalam, Adel Alhowyan, Sulaiman S. Alhudaithi, et al.
Applied Sciences (2023) Vol. 13, Iss. 19, pp. 10859-10859
Open Access | Times Cited: 1
Oleic acid and linoleic acid nanosomes boost immunity and provoke cell death via the upregulation of beta-defensin-4 at genetic and epigenetic levels
Gamaleldin I. Harisa, Ibrahim Najashi, Ahmed H. Bakheit, et al.
Open Chemistry (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Design and Synthesis of Gefitinib Derivatives as Potential Drugs fo r Cancer Treatment: Antiproliferative Activity, Molecular Docking, and ADMET Prediction
Xiaoyan Ma, Min Shan, Yunlong Lu
Letters in Drug Design & Discovery (2023) Vol. 21, Iss. 9, pp. 1555-1568
Closed Access
Specific Application of Lipid-Based Nanoparticular Drug Delivery Systems for Cancer Therapy
Melike Üner
Springer eBooks (2023), pp. 1-37
Closed Access
Page 1

Scroll to top